- Current Kane Biotech board member Mark Nawacki will take over as Chairman of the Board
- Mark is currently the President & CEO of Searchlight Pharma Inc., a Canadian-based specialty pharmaceutical company
- Mark holds an MBA from the University of Toronto and is a Canadian-designated CPA
- Kane Biotech is a biotechnology company
- Kane Biotech is trading unchanged at C$0.12 at 10:45 am EST
Kane Biotech (KNE) announced that current board member Mark Nawacki will take over as Chairman of the Board.
Philip Renaud will assume the role of Vice-Chair.
“Over the past two years, we have made significant progress developing and commercializing our technologies in both animal health and skincare where we’ve built two very promising businesses.
As outgoing Chairman and largest shareholder, it is my belief that as the company approaches a number of anticipated inflection points in Wound Care, it would be best served by having an experienced executive with a deep understanding of the biotechnology sector in Canada and around the world. I will remain a board member and will look to grow my position in Kane Biotech as Marc Edwards, CEO, and his team continue to achieve their ambitious goals,” commented Philip Renaud, Vice-Chair and outgoing Chairman.
Mark Nawacki is currently the President & CEO of Searchlight Pharma Inc., a Canadian-based specialty pharmaceutical company focused on the acquisition and commercialization of innovative and unique healthcare and pharmaceutical products.
Prior to this, Mr. Nawacki served as Executive Vice President, Business and Corporate Development of Paladin Labs, a leading Canadian specialty pharmaceutical company, from 2003 to 2014.
Mr. Nawacki holds a BA in International Relations and Russian and East European Studies from the University of Toronto (Trinity), an MBA also from the University of Toronto, and is a Canadian-designated CPA. He also currently sits on the Board of Intelgenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT).
Incoming Chairman Mark Nawacki commented, “Firstly I would like to thank Philip for all his hard work and stewardship of Kane Biotech. I am honoured to take the role of Chairman to guide the Company to the next level and draw from my experience of successfully commercializing technologies”.
Kane Biotech is a biotechnology company engaged in the research and development of technologies and products that prevent and remove microbial biofilms.
The company has a portfolio of biotechnologies, intellectual property and products developed by the company’s own biofilm research expertise and acquired from leading research institutions.
Kane Biotech is trading unchanged at C$0.12 at 10:45 am EST.